Vac­cine sales are ex­pect­ed to fade af­ter a Q1 pop at As­traZeneca, but a slate of suc­cess­ful fran­chis­es buoys fore­cast

All the pis­tons dri­ving rev­enue growth were pump­ing dur­ing As­traZeneca’s Q1, with Alex­ion con­tribut­ing to strong per­for­mance in the Big Phar­ma’s swelling on­col­o­gy busi­ness. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER